IL-12/23p40 Neutralization in Combination with Sirolimus for Prevention of Acute Graft Vs. Host Disease Joseph Pidala, MD, PhD, Francisca Beato, BS,

Slides:

Advertisements

Similar presentations

Identification of CD137+ IFN-g- CD4+ Alloreactive T Cells Post Myeloablative Double Cord Blood Transplant: A Synergistic Role in the Graft Verus Graft.

Advertisements

Many Days at Home during Neutropenia after Allogeneic Hematopoietic Stem Cell Transplantation Correlates with Low Incidence of Acute Graft-versus-Host.

Sirolimus in Combination with Cyclosporine or Tacrolimus Plus Methotrexate for Prevention of Graft-versus-Host Disease following Hematopoietic Cell Transplantation.

Biology of Blood and Marrow Transplantation

Promising Progression-Free Survival for Patients Low and Intermediate Grade Lymphoid Malignancies after Nonmyeloablative Umbilical Cord Blood Transplantation

Hypertension and Diabetes Mellitus in Adult and Pediatric Survivors of Allogeneic Hematopoietic Cell Transplantation Navneet S. Majhail, MD, MS, Tejo.

Mohamed A. Kharfan-Dabaja, Claudio Anasetti, Edgardo S. Santos

Pretransplantation 5-Azacitidine in High-Risk Myelodysplastic Syndrome

T-Cell Acute Lymphoblastic Lymphoma (T-LBL) and Stem Cell Transplantation (SCT): A Comparison of Outcomes with T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Liver Transplantation for Hepatic Graft-Versus-Host-Disease: A United Network for Organ Sharing (UNOS) Database Study Shahrukh Hashmi, MD MPH, Timucin.

Efficacy of Rituximab in the Setting of Steroid-Refractory Chronic Graft-versus-Host Disease: A Systematic Review and Meta-Analysis Mohamed A. Kharfan-Dabaja,

Infusion of Ex Vivo Expanded Cord Blood Progenitor Cells Is Associated with Reduced Hospital Days and Utilization of Opiate Infusion and Total Parenteral.

Many Days at Home during Neutropenia after Allogeneic Hematopoietic Stem Cell Transplantation Correlates with Low Incidence of Acute Graft-versus-Host.

IL-12hi Rapamycin-Conditioned Dendritic Cells Mediate IFN-γ-Dependent and Fas- Supported Apoptosis of Alloreactive CD4+ T Cells and Inhibit Graft-Versus-Host.

Sympathectomy Protects Denervated Skin from Graft-Versus-Host Disease

Vitamin A Deficiency Is Associated with Increased Risk of Acute Graft Versus Host Disease in Children Dana T. Lounder, MD, Sonata Jodele, MD, Pooja Khandelwal,

Lymphocyte Recovery Is a Major Determinant of Outcome after Matched Unrelated Myeloablative Transplantation for Myelogenous Malignancies Katarina Le.

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Low Incidence of Chronic GVHD after HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post Transplantation Cyclophosphamide in Older.

A First-in-Disease Trial of in Vivo Costimulation Blockade for GVHD Prevention: The Addition of Abatacept to Standard GVHD Prophylaxis Controls Early.

Sabina Kersting, Leo F. Verdonck

Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival Mary.

TIM-1 Blockade of the Donor Graft Provides Protection Against Lethal Gvhd Bettina P. Iliopoulou, PhD, Katie Hsu, MS, Antonio Pierini, MD, Gordon J. Freeman,

ATG Prevents Severe Acute Graft-versus-Host Disease in Mismatched Unrelated Donor Hematopoietic Cell Transplantation Joseph Pidala, Marcie Tomblyn, Taiga.

Extracorporeal Photopheresis in Steroid-Refractory Acute or Chronic Graft-versus-Host Disease: Results of a Systematic Review of Prospective Studies

Decision Analysis of Peripheral Blood versus Bone Marrow Hematopoietic Stem Cells for Allogeneic Hematopoietic Cell Transplantation Joseph Pidala, Claudio.

Impact of Ocular Chronic Graft-versus-Host Disease on Quality of Life

Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic.

Deficiency of MyD88 Signaling in CD4 Tconvs Increases Tregs Suppression through Loss of ST2 Signaling, Reducing Acute Graft-Versus-Host Disease in Multiple.

Low Relapse without Excessive Transplant-Related Mortality following Myeloablative Cord Blood Transplantation for Acute Leukemia in Complete Remission:

Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients:

Ofatumumab in Combination with Glucocorticoids for Primary Therapy of Chronic Graft- versus-Host Disease: Phase I Trial Results Joseph Pidala, Jongphil.

Claudio Brunstein, MD, PhD, Keli Hippen, Todd E

Helicobacter pylori Infection and Graft-versus-Host Disease

Dysglycemia Following Glucocorticoid Therapy for Acute Graft-versus-Host Disease Adversely Affects Transplantation Outcomes Joseph Pidala, Jongphil Kim,

Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation Lindsay G. Jensen, Tracey Stiller,

A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse Zeyad Kanaan, MD, William Tse, MD, FACP

Fludarabine and Pharmacokinetic-Targeted Busulfan before Allografting for Adults with Acute Lymphoid Leukemia Stella Santarone, Joseph Pidala, Marta.

Joseph Pidala, Stephanie J

Paul J. Martin, Terry Furlong, Scott D. Rowley, Steven A

A Phase I/II Study of Mycophenolate Mofetil in Combination with Cyclosporine for Prophylaxis of Acute Graft-versus-Host Disease after Myeloablative Conditioning.

Fludarabine and 2-Gy TBI is Superior to 2 Gy TBI as Conditioning for HLA-Matched Related Hematopoietic Cell Transplantation: A Phase III Randomized Trial

Biology of Blood and Marrow Transplantation

Total Body Irradiation–Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation.

Iron Overload Manifesting as Apparent Exacerbation of Hepatic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation Rammurti.

Feasibility of Treating Post-Transplantation Minimal Residual Disease in Children with Acute Leukemia Nirali N. Shah, Michael J. Borowitz, Nancy C. Robey,

Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and Mini-Methotrexate (Tac/Sir/MTX) as Acute Graft-versus-Host Disease.

Possible Association between Obesity and Posttransplantation Complications Including Infectious Diseases and Acute Graft-versus-Host Disease Shigeo Fuji,

Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation Rachel B. Salit, Filippo.

Mohammad Alhyari, M. D. , Aymen Bukannan, M. D. , Kimberly Brown, M. D

CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft- versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

Reduced Incidence of Acute and Chronic Graft-versus-Host Disease with the Addition of Thymoglobulin to a Targeted Busulfan/Cyclophosphamide Regimen H.

Use of Myeloablative or Reduced Intensity Conditioning with Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia and MDS is Associated.

Predictors of Non-Relapse Mortality Among Patients Treated with Sirolimus- Vs. Non- Sirolimus-Containing Immune Suppression for Graft-Versus-Host Disease.

High Incidence of Severe Acute Graft-Versus-Host Disease with Tacrolimus and Mycophenolate Mofetil in a Large Cohort of Related and Unrelated Allogeneic.

Reduced-Intensity Allogeneic Transplant in Patients Older Than 55 Years: Unrelated Umbilical Cord Blood Is Safe and Effective for Patients without a Matched.

Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: Hematologic Malignancy Outcomes Are Not Impaired in Advanced.

Mohamed A. Kharfan-Dabaja, Yasser R. Abou Mourad, Hugo F

Therapeutic Immunosuppression Concentrations on Day 0 and the Development of Acute Graft Versus Host Disease (GVHD) in Hematopoietic Stem Cell Transplantation.

C-Reactive Protein Levels at Diagnosis of Acute Graft-versus-Host Disease Predict Steroid-Refractory Disease, Treatment-Related Mortality, and Overall.

A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation:

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Inhibition of Human Dendritic Cell ER Stress Reduces Gvhd Without Impairing Tregs, NK Cells, or Anti-Tumor Ctl Brian Christopher Betts, Frederick L.

Identification of CD137+ IFN-g- CD4+ Alloreactive T Cells Post Myeloablative Double Cord Blood Transplant: A Synergistic Role in the Graft Verus Graft.

Maximally Tolerated Busulfan Systemic Exposure in Combination with Fludarabine as Conditioning before Allogeneic Hematopoietic Cell Transplantation Janelle.

Longitudinal Assessment of Morbidity and Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation: Retrospective Analysis of a.

Close Monitoring of Cyclosporine A Concentration as a Means of Preventing Acute Graft-Versus-Host Disease in Allogeneic Stem Cell Recipients Marietta.

Infliximab for Managing Steroid-Refractory Acute Graft-versus-Host Disease Joseph Pidala, Jongphil Kim, Teresa Field, Ali McBride, Mohamed Kharfan-Dabaja,

Graft Versus Leukemia Effect Is Overestimated in Studies with High Rates of Graft Versus Host Disease Related Mortality: A Simulation Study Murtadha.

Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor–Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord.

Presentation transcript:

IL-12/23p40 Neutralization in Combination with Sirolimus for Prevention of Acute Graft Vs. Host Disease Joseph Pidala, MD, PhD, Francisca Beato, BS, Jongphil Kim, PhD, Melissa Alsina, MD, Ernesto Ayala, MD, Brian Betts, MD, Hugo Fernandez, MD, Teresa Field, MD, PhD, Heather Jim, PhD, Linda Kelley, PhD, Mohamed Kharfan-Dabaja, MD, Frederick L. Locke, MD, Asmita Mishra, MD, Michael L. Nieder, Taiga Nishihori, MD, Jose-Leonel Ochoa-Bayona, MD, Lia Elena Perez, MD, Marcie L. Riches, MD, MS, Anandaraman Veerapathran, PhD, Claudio Anasetti, MD Biology of Blood and Marrow Transplantation Volume 21, Issue 2, Pages S344-S345 (February 2015) DOI: 10.1016/j.bbmt.2014.11.548 Copyright © 2015 Terms and Conditions

Figure 1 (a) Treg suppressive units, defined as (absolute Treg)/(absolute Treg capable of achieving 50% suppression of CD4+CD25- T responders with CD3/CD28 stimulus) at day 30 post-HCT, (b) cumulative incidence of grade II-IV acute GVHD, (c) mean weekly prednisone dose/kg recipient body weight among patients without death or malignancy relapse, and (d) relapse-free survival from time of HCT Biology of Blood and Marrow Transplantation 2015 21, S344-S345DOI: (10.1016/j.bbmt.2014.11.548) Copyright © 2015 Terms and Conditions